In this interview, CEO Martin Gouldstone of Oncimmune (ONC ) - a leading life sciences firm offering autoantibody profiling services to the Biopharma & CROs industries – takes me through :
00:00 What the company does and the future growth in precision medicine
07:20 New application area in human longevity/ageing
10:25 Current client demand
12:00 Update on ONC’s commercialisation/turnaround strategy
13:25 Outlook & goals for FY25
16:15 Cash runway ahead
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
